PMID- 33780266
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20220131
IS  - 2688-1535 (Electronic)
IS  - 2688-1527 (Linking)
VI  - 17
IP  - 11
DP  - 2021 Nov
TI  - Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for 
      Patients Receiving Ipilimumab for Metastatic Melanoma.
PG  - e1631-e1638
LID - 10.1200/OP.20.00845 [doi]
AB  - PURPOSE: Ipilimumab is an effective treatment for melanoma; however, toxicity 
      rates remain high. The objective of this study was to describe the rates of 
      adverse events (AEs), emergency room (ER) visits, hospitalizations, and nursing 
      resource utilization for patients enrolled in a nurse-led telephone toxicity 
      monitoring program. METHODS: Patients received weekly telephone calls from 
      nursing to review a toxicity checklist during ipilimumab treatment and for 8 
      weeks after completion. To evaluate this program, a single-center retrospective 
      review was performed for patients treated between July 2012 and September 2017 
      with single agent ipilimumab for advanced melanoma. Data were collected up to 3 
      months post-ipilimumab. RESULTS: A total of 67 patients were included, with a 
      mean (standard deviation) age of 61 (14.6) years. Thirty-three (49%) patients 
      received four doses of ipilimumab, and 17 (25%) had one dose delay. The median 
      (IQR) of any AEs reported per patient was 11 (8-17). There were 44 (66%) patients 
      with AEs deemed to be definitely or probably related to ipilimumab, and of those, 
      3 (4%) experienced a grade 3 AE, whereas 4 (6%) experienced grade 4 AEs. Twenty 
      patients (30%) had ER visits, and 31 (46%) were hospitalized during follow-up (9% 
      ER visits and 6% hospitalizations were related to drug toxicity). CONCLUSION: 
      Ipilimumab is associated with high rates of toxicity; however, a proactive 
      nurse-led monitoring program was feasible and patients had low rates of grade 3-4 
      toxicity. Hospitalization rates and ER visits remained high; however, the 
      minority of those were related to drug toxicity.
FAU - Menjak, Ines B
AU  - Menjak IB
AUID- ORCID: 0000-0002-4239-0858
AD  - Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 
      Toronto, Ontario, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Elias, Evelyn S
AU  - Elias ES
AD  - Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, 
      Canada.
FAU - Jain, Sheena
AU  - Jain S
AD  - Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, 
      Canada.
FAU - Lawrie, Deborah
AU  - Lawrie D
AD  - Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, 
      Canada.
FAU - Petrella, Teresa M
AU  - Petrella TM
AD  - Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 
      Toronto, Ontario, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20210329
PL  - United States
TA  - JCO Oncol Pract
JT  - JCO oncology practice
JID - 101758685
RN  - 0 (Ipilimumab)
SB  - IM
MH  - Humans
MH  - Immunotherapy
MH  - Ipilimumab/adverse effects
MH  - *Melanoma/drug therapy
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Skin Neoplasms/drug therapy
COIS- Ines B. MenjakHonoraria: Bristol Myers SquibbConsulting or Advisory Role: Amgen, 
      AstrazenecaResearch Funding: Bristol Myers Squibb, AstraZeneca, Takeda Teresa M. 
      PetrellaHonoraria: Bristol Myers Squibb, Merck, Novartis, Sanofi/Regeneron, 
      Pfizer, Sun PharmaConsulting or Advisory Role: Merck, Bristol Myers, Novartis, 
      Sanofi/Regeneron, Pfizer, Sun PharmaResearch Funding: Roche Canada, Novartis 
      Canada Pharmaceuticals IncNo other potential conflicts of interest were reported.
EDAT- 2021/03/30 06:00
MHDA- 2022/02/01 06:00
CRDT- 2021/03/29 17:09
PHST- 2021/03/30 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/03/29 17:09 [entrez]
AID - 10.1200/OP.20.00845 [doi]
PST - ppublish
SO  - JCO Oncol Pract. 2021 Nov;17(11):e1631-e1638. doi: 10.1200/OP.20.00845. Epub 2021 
      Mar 29.